Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2014-07-04

Clinical Trial Update: Intravaginal LACTIN-V for Prevention of Recurrent Urinary Tract Infection [Phase 2]

View source ↗

Summary

Phase 2 trial update for intravaginal LACTIN-V aimed at preventing recurrent urinary tract infections has completed with results posted in 2014.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Lactin-V (Lactobacillus crispatus CTV-05)

Snippet

Sponsor: University of Washington | Conditions: Urinary Tract Infection | Phase 2 | Status: COMPLETED | Results posted: 2014-07-04